ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Brief description of study

To determine in the context of a randomized trial whether the Event-Free Survival of patients with newly diagnosed high-risk NBL is improved with the addition of I-MIBG during Induction, prior to tandem autologous stem cell transplantation (ASCT).


Clinical Study Identifier: s19-00979
ClinicalTrials.gov Identifier: NCT03126916
Principal Investigator: Sharon L Gardner.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.